11.23.22 -- Merck, Medimmune, And Keytruda: An Ultimate Outsourcing Story

How can drug sponsors and developers leverage these increasingly strategic commercial fill/finish partnerships? Explore tips on how to put programs on a firmer footing.

Expression of inclusion bodies has historically suffered a bad reputation in the industry. So, how do these two routes, soluble and insoluble, compare in terms of their advantages and challenges?

A review of insights derived from the development of mRNA-based COVID-19 vaccines and how they can be applied to accelerate progress in the manufacture of vaccines and therapeutics moving forward.

Learn what indicates whether a service provider has the capabilities desired by a drug sponsor to fulfill a company’s long-term goals and is committed to their success.

This guide shares the steps involved in formulation development, considerations during formulation, and how partnering with an experienced CDMO can lead to a successful commercial product.

A manufacturing partner that can't manage the complexities of your biologic can cause problems large and small, putting your next level of funding, or even the future of your company, in jeopardy.

We explain how to successfully address common process development challenges to achieve an efficient journey to market and maximize the biotherapeutic’s potential impact.

Learn about our transition to closed processes for expansion of suspension CHO and Sf9 cells and how the closed system compares to traditional processing.

How do you know if an intensification approach will provide advantages? Three process intensification experts show how different intensification approaches affect outputs using different scenarios.